Anti-CD93 Antibody
Lung Squamous Cell Carcinoma (LUSC)
PreclinicalActive (seeking partnership)
Key Facts
Indication
Lung Squamous Cell Carcinoma (LUSC)
Phase
Preclinical
Status
Active (seeking partnership)
Company
About Montis Biosciences
Montis Biosciences is a private, preclinical-stage biotech founded in 2021 and based in Leuven, Belgium. The company's core innovation is a platform for discovering dual-mechanism anti-C1q antibodies designed to inhibit the classical complement pathway while also modulating C1q's complement-independent effects on myeloid cells, offering a novel approach in neuroinflammation. With a lead program in Guillain-Barré syndrome and a partnered oncology asset, Montis is backed by a strong syndicate of life science investors including Pfizer Ventures and VIB.
View full company profile